Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Acetaminophen Tablets

CGMP Deviations: The recalled acetaminophen tablet lot was not manufactured under current good manufacturing practices as noted by a recent inspection of the manufacturing firm.

Terminated cGMP deviation Marlex Pharmaceuticals, Inc. NDC 10135-152-01 D-1064-2013
Class III · Low risk

Disulfiram Tablets USP 250 mg

CGMP Deviation; cotton coil is missing in some packaged bottles

Terminated cGMP deviation Teva Pharmaceuticals USA, Inc. NDC 0093-5035-01 D-578-2013
Class II · Moderate risk

Benjamins Infants Gripe Mixture

CGMP Deviations: this product is being recalled because an FDA inspection revealed that it was not manufactured under current good manufacturing practices.

Terminated cGMP deviation Carib Import & Export, Inc. D-307-2013
Class II · Moderate risk

Medi-bolic Booster Injectable

CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.

Terminated cGMP deviation RX South LLC DBA RX3 Pharmacy D-191-2013
Class II · Moderate risk

ABILIFY (aripiprazole)

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Terminated cGMP deviation Bristol Myers Squibb Manufacturing Company NDC 59148-011-35 D-181-2013
Class III · Low risk

Lemon Hand Sanitizing Wipes

CGMP Deviations: The products were manufactured with raw material which contain unknown particles believed to be water and dirt.

Terminated cGMP deviation ITW Dymon D-056-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1328-01 D-085-2013
Class II · Moderate risk

Thyro-Tab 0.300 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-084-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1331-01 D-083-2013
Class II · Moderate risk

Thyro-Tab 0.137 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-082-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1324-01 D-081-2013
Class II · Moderate risk

Thyro-Tab 0.125 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-080-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1330-01 D-079-2013
Class II · Moderate risk

Thyro-Tab 0.112 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-078-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1329-01 D-077-2013
Class II · Moderate risk

Thyro-Tab 0.088 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-076-2013
Class II · Moderate risk

Levothroid

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa NDC 0456-1321-01 D-075-2013
Class II · Moderate risk

Thyro-Tab 0.050 mg.

cGMP Deviations; does not meet in process specification requirements

Terminated cGMP deviation Lloyd Inc. of Iowa D-074-2013
Class II · Moderate risk

Oxygen

CGMP Deviations; no identity or purity testing on incoming oxygen gas, and lack of documentation

Terminated cGMP deviation Oklahoma Respiratory Care Inc D-1445-2012
Class II · Moderate risk

Cardiogen-82

GMP deviation; Sr-82 levels exceeded alert limit specification

Terminated cGMP deviation Bracco Diagnostics Inc NDC 0270-0091-01 D-1684-2012